Ron brings extensive leadership experience across biotechnology strategy, corporate development, and operational execution. In his advisory role, he provides guidance on long-term strategy, partnerships, and organizational growth as Therna expands its platform capabilities and therapeutic programs.

Ron currently serves as a Board Member for City Therapeutics and Harmony Biosciences. He previously served as Chief Executive Officer and Board Member of Orbital Therapeutics, until it was acquired by Bristol Myers Squibb, and was previously Chief Executive Officer of Spark Therapeutics, which was acquired by Roche.